Company
LON:SAR
Sareum Holdings (AIM:SAR) is a clinical-stage biotechnology company developing next generation kinase inhibitors for autoimmune disease and cancer. The Company is focused on developing next generation small molecules which modify the activity of the JAK kinase family and have best-in-class potential. Its lead candidate, SDC-1801, simultaneously inhibits TYK2 and JAK1. SDC-1801 is a potential treatment for a range of autoimmune diseases, including psoriasis, and has completed Phase 1 clinical development.
239 stories · page 7 of 12
Sareum thinks SDC-1801 is the most potent in the series of compounds and will now take it through pre-clinical development before advancing into human trials, which could begin as early as 2020
The UK's index of leading shares added 1.6 points, or 0.02% , to finish at 7,279, while sterling was up 0.80% against the US dollar
SRA737 is a checkpoint kinase-1 inhibitor, one of a new breed of treatments
Archive
A glance at some of the day's highlights from the Proactive Investors newswire
Archive
A glance at some of the day's highlights from the Proactive Investors newswire
A look at some of the biggest risers and fallers in London on Friday afternoon...
The UK's top share index shed over 131 points at 7,633, while mid-cap brother FTSE 250 was also lower
Investments and investor services
A look at the day's major movers, featuring Strategic Minerals, Avanti Communications, Transense, BlueRock Diamonds and Stratex
The Aurora+FLT3 kinase inhibitors were being developed by Hebei Medical University Biomedical Engineering Center
Archive
A glance at some of the day's highlights from the Proactive Investors newswire
"We are very pleased with the progress that Sierra Oncology has made across its clinical trials and future plans with SRA737,” said Dr Tim Mitchell
Archive
A glance at some of the day's highlights from the Proactive Investors newswire
A glance at some of the day's highlights from the Proactive Investors newswire
A look at some of the biggest risers and fallers in London on Tuesday
Stocks consolidated gains at the death with bid stock Shire the best performing blue-chip
Currently, SRA737 is in phase I/II clinical trials as a single therapy to treat certain stress-driven cancers
Archive
A glance at some of the day's highlights from the Proactive Investors newswire
Archive
A glance at some of the day's highlights from the Proactive Investors newswire
